Novartis AG
Change company Symbol lookup
Select an option...
NVS Novartis AG
FRBA FIRST BANK (Hamilton)
UNM Unum Group
LLY Eli Lilly and Co
BDC Belden Inc
TTM Tata Motors Ltd
HOG Harley-Davidson Inc
SKY Skyline Champion Corp
MMM 3M Co
MPX Marine Products Corp
Go

Health Care : Pharmaceuticals | Large Cap Value
Based in Switzerland
Company profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$79.16
Day's Change
-1.79 (-2.21%)
Bid
--
Ask
--
B/A Size
--
Day's High
79.72
Day's Low
78.58
Volume
(Heavy Day)

Today's volume of 631,408 shares is on pace to be much greater than NVS's 10-day average volume of 1,640,966 shares.

631,408

Diabetes Drugs Market to Expand at 6.1% CAGR to Reach US$ 78,261.7 Mn by 2026 | Global Market Size, Share, Analysis, Forecast [2019-2026]

6:28 am ET August 19, 2020 (Globe Newswire) Print

The global diabetes drugs market derives growth from advancements in drug delivery systems. According to a report published by Fortune Business Insights, titled "Diabetes Drugs: Global Market Analysis, Insights and Forecast, 2019-2026," the market was valued at US$ 48,753.1 Mn in 2018. Fortune Business Insights has predicted that the market will be valued at US$ 78,261.7 Mn by the end of 2026, thereby exhibiting a CAGR of 6.1%.

The other highlights of the report include:

? Targeted analysis of the impact of COVID-19 on the market;

? Detailed study of the factors, trends, and constraints shaping the market;

? Careful evaluation of the regional dynamics influencing the market; and

? Thorough profiling and examination of the key market players and their strategies.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/diabetes-drugs-market-100570

Availability of Low-Cost Insulin to Boost the Market

Insulin is one of the most widely used drugs for the treatment of diabetes. The exceptional properties and clinical efficacy of insulin have led to a rising uptake. Despite high efficacy, the cost associated with insulin has been a barrier towards the growth of insulin.

Considering this factor, many companies are exploring potential ways to the reduced cost associated with insulin for management of diabetes. In 2019, Eli Lilly and Company, launched a new insulin drug, that was almost half the price of its previous brands. Eli Lilly announced the low-cost insulin 'Lispro', a product that was priced significantly less than its previous Humalog injection.

Fortune Business Insights' latest report on the global diabetes drugs market is an encompassment of such product advancements. The report gauges the impact of product innovations, similar to Lispro, on the global market.

The global economy is in absolute turmoil because of the COVID-19 pandemic outbreak. Some industries remain largely unaffected by the outbreak, some are thriving, but most are in doldrums. Although the healthcare industry is flourishing, certain markets within the industry are experiencing staggered growth. Wading through these troubled times is a difficult task and Fortune Business Insights(TM) aims at equipping your business with the most comprehensive market insights, collated and analyzed by our expert and experienced research team.

Click here to get the short-term and long-term impact of COVID-19 on this market.

Please visit: https://www.fortunebusinessinsights.com/industry-reports/diabetes-drugs-market-100570

Encouraged by High Demand, Glenmark Extends Insulin Sales in India

In 2019, Glenmark Pharmaceuticals announced that it plans to bring its Remogliflozin Etabonate to India. The high demand for diabetes drugs in India has influenced Glenmark's latest move. Additionally, a huge diabetic patient pool has also contributed to the high demand for diabetes drugs in India.

Such competitor moves have aided the growth of the global diabetes drugs market. The report includes company activities, similar to the aforementioned case. The report includes detailed analysis of company activities such as takeovers, mergers and acquisitions, agreements, and investment.

Increasing Drug Approvals Have a Positive Impact on Overall Market

The high prevalence of diabetes on a global scale has paved way for several clinical trials. Increasing drug approvals have aided the growth of the global diabetes drugs market. Novo Nordisk's 2018 launch of Ozempic and Fiasp is a perfect example of the aforementioned case. Additionally, the company received approval from the Food and Drug Administration and this has aided the business expansion of Novo Nordisk. The company's latest drug approvals will bode well for the global diabetes market and is likely to enable growth of the market in the coming years.

Fortune Business Insights has summarized the impact of several companies on the global diabetes drugs market. Furthermore, Fortune Business Insights has labelled out leading companies that have made significant contributions to the growth of the global diabetes drugs market.

Quick Buy - Diabetes Drugs Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100570

Some of the leading companies that are operating in the global diabetes drugs market are

-- Novo Nordisk A/S

-- Sanofi

-- Merck & Co., Inc.

-- Eli Lilly and Company

-- AstraZeneca

-- Takeda Pharmaceutical Company Limited

-- Boehringer Ingelheim International GmbH

-- Novartis AG

-- Johnson & Johnson Services, Inc.

-- Bayer AG

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/diabetes-drugs-market-100570

Diabetes Drugs Market Segmentation:

By Drug Class

? Insulin

? DPP-4 Inhibitors

? GLP-1 Receptor Agonists

? SGLT2 Inhibitors

? Others

By Diabetes Type

? Type 1

? Type 2

By Route of Administration

? Oral

? Subcutaneous

? Intravenous

By Distribution Channel

? Online pharmacies

? Hospital Pharmacies

? Retail Pharmacies

By Geography

? North America (U.S. and Canada)

? Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

? Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

? Latin America (Brazil, Mexico, and Rest of Latin America)

? Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/diabetes-drugs-market-100570

Have a Look at Related Reports:

Diabetes Treatment Devices Market Share and Global Trend By Product (Insulin Pens, Insulin Pumps, Insulin Jet Injectors, Insulin Syringes, Others), By Distribution Channel (Institutional Sales (Hospitals, Clinics), Retail Sales (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)) & Geography Forecast till 2026

Diabetes Devices Market Share and Global Trend By Product (Monitoring Devices, Treatment Devices), By Distribution Channel (Institutional Sales, Retail Sales) and Geography Forecast till 2026

Human Insulin Market Share & Industry Analysis, By Type (Analogue Insulin, Traditional Human Insulin), By Diabetes Type (Type 1, Type 2), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), and Regional Forecast, 2019-2026

Blood Glucose Monitoring Systems Market Share & Industry Analysis, By Device (Continuous Blood Glucose Monitoring Systems, Self-monitoring of Blood Glucose Systems), By Type (Invasive, Non-invasive), By Modality (Wearable, Non-wearable), By Distribution Channel (Institutional Sales, Retail Sales), and Regional Forecast 2019-2026

Insulin Pens Market Share and Global Trend By Product Type (Disposable, Reusable), By Application (Type 1 Diabetes, Type 2 Diabetes), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies, Diabetes Clinics), Geography Forecast till 2026

About Us:

Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights(TM) we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights(TM) Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune - 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Fortune Business Insights(TM)

LinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/diabetes-drugs-market-9136

https://ml.globenewswire.com/media/05408ba1-26b1-4fdd-8f48-1af4df373348/small/fbi-logo-tm-png.png

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.